903528-73-4

Upstream product

• 179756-87-7 2-(4-chlorobutyl)-4-methyl-1,2,4-triazine-3,5(2H,4H)-dione 
• 1011-17-2 2-hydroxyphenylpiperazine 

Downstream Products

• 1351409-39-6 2-(4-{4-[2-(2-fluoroethoxy)phenyl]piperazin-1-yl}butyl)-4-methyl-1,2,4-triazine-3,5(2H,4H)-dione 
• 1346454-27-0 C₁₉H₂₆⁽³⁾HN₅O₃ 
• 1346454-28-1 [¹⁸F]-2-(4-{4-[2-(2-fluoroethoxy)phenyl]piperazin-1-yl}butyl)-4-methyl-1,2,4-triazine-3,5(2H,4H)-dione 

Relevant academic research and scientific papers

Synthesis and evaluation of arylpiperazines derivatives of 3,5-dioxo-(2H,4H)-1,2,4-triazine as 5-HT1AR ligands

5-HT1AR agonist or partial agonists are established drug candidates for psychiatric and neurological disorders. We have reported the synthesis and evaluation of a series of high affinity 5-HT1AR partial agonist PET imaging agents with greater selectivity over α-1AR. The characteristic of these molecules are 3,5-dioxo-(2H,4H)-1,2,4-triazine skeleton tethered to an arylpiperazine unit through an alkyl side chain. The most potent 5-HT1AR agonistic properties were found to be associated with the molecules bearing C-4 alkyl group as the linker. Therefore development of 3,5-dioxo-(2H,4H)-1,2,4-triazine bearing arylpiperazine derivatives may provide high affinity selective 5-HT1AR ligands. Herein we describe the synthesis and evaluation of the binding properties of a series of arylpiperazine analogues of 3,5-dioxo-(2H,4H)-1,2,4-triazine.

RADIOLABELED COMPOUNDS AND METHODS THEREOF

The present invention relates to radiodiagnostic compounds, methods of making those compounds, and methods of use thereof as imaging agents for preferably a HA serotonin 5-HT1A receptor for use in PET or SPECT, preferably PET. Compositions comprising an imaging-effective amount of radiolabeled compounds are also disclosed. The present invention also relates to non-radiolabeled compounds, methods of making those compounds, and methods of use thereof to treat various neurological and/or psychiatric disorders.